Nanobiotix(GB:0QAV)
€27.88-1.12 (-3.86%)
GB:0QAV
Nanobiotix financials statements
€27.88
At close:-1.12 (-3.86%)
Nanobiotix (0QAV) Ratios
4 Followers
Nanobiotix Ratios
GB:0QAV's free cash flow for Q2 2026 was €-22.66M. For the 2026 fiscal year, GB:0QAV's free cash flow was decreased by €-627.00K and operating cash flow was €-22.03M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Mar 23 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.09 | 1.04 | 1.75 | 1.38 | 2.53 |
| Quick Ratio | 1.09 | 1.04 | 1.75 | 1.38 | 2.53 |
| Cash Ratio | 0.92 | 0.84 | 1.51 | 1.02 | 2.28 |
| Solvency Ratio | -0.15 | -0.50 | -0.40 | -0.64 | -0.61 |
| Operating Cash Flow Ratio | -0.58 | -0.33 | -0.25 | -1.00 | -0.84 |
| Short-Term Operating Cash Flow Coverage | -10.78 | -5.34 | -3.26 | -10.57 | -4.38 |
| Net Current Asset Value | € -89.49M | € -71.66M | € -8.40M | € -34.46M | € 18.08M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 1.41 | 0.76 | 0.54 | 0.89 | 0.45 |
| Debt-to-Equity Ratio | -1.13 | -0.77 | -27.44 | -1.97 | 1.72 |
| Debt-to-Capital Ratio | 8.80 | -3.44 | 1.04 | 2.04 | 0.63 |
| Long-Term Debt-to-Capital Ratio | 19.22 | -1.90 | 1.05 | 2.59 | 0.55 |
| Financial Leverage Ratio | -0.80 | -1.03 | -50.95 | -2.21 | 3.81 |
| Debt Service Coverage Ratio | -0.89 | -5.25 | -2.56 | -5.27 | -5.56 |
| Interest Coverage Ratio | -1.04 | -8.46 | -3.35 | -8.65 | -78.36 |
| Debt to Market Cap | 0.10 | 0.33 | 0.19 | 0.38 | 0.16 |
| Interest Debt Per Share | 2.23 | 1.25 | 1.59 | 1.69 | 1.34 |
| Net Debt to EBITDA | -3.53 | -0.02 | 0.82 | -0.27 | 0.83 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | 100.00% | 100.00% | 68.59% | 26470.00% |
| EBIT Margin | -45.75% | 544.80% | -105.12% | -1157.56% | -471650.00% |
| EBITDA Margin | -40.71% | 530.83% | -100.09% | -1126.15% | -456050.00% |
| Operating Profit Margin | -36.49% | 589.13% | -89.09% | -1057.22% | -525790.00% |
| Pretax Profit Margin | -80.82% | 586.02% | -131.68% | -1279.77% | -494890.00% |
| Net Profit Margin | -80.83% | 586.89% | -132.08% | -1194.33% | -470030.00% |
| Continuous Operations Profit Margin | -80.83% | 586.89% | -132.08% | -1194.33% | -470030.00% |
| Net Income Per EBT | 100.01% | 100.15% | 100.30% | 93.32% | 94.98% |
| EBT Per EBIT | 221.46% | 99.47% | 147.80% | 121.05% | 94.12% |
| Return on Assets (ROA) | -35.36% | -101.06% | -42.28% | -95.44% | -46.23% |
| Return on Equity (ROE) | 28.36% | 103.70% | 2154.10% | 210.91% | -176.09% |
| Return on Capital Employed (ROCE) | -105.51% | -806.22% | -60.83% | -231.27% | -81.11% |
| Return on Invested Capital (ROIC) | -74.29% | -510.16% | -54.60% | -178.54% | -68.38% |
| Return on Tangible Assets | -35.37% | -101.07% | -42.28% | -95.44% | -46.23% |
| Earnings Yield | -2.59% | -47.73% | -16.27% | -45.21% | -18.51% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.86 | -1.36 | 3.17 | 1.68 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.38 | -0.53 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 6.49 | -2.10 | 4.81 | 0.67 | 0.00 |
| Asset Turnover | 0.44 | -0.17 | 0.32 | 0.08 | 0.00 |
| Working Capital Turnover Ratio | 7.63 | -0.58 | 1.16 | 0.14 | 0.00 |
| Cash Conversion Cycle | 94.57 | -268.35 | 115.30 | -755.89 | 142421.02 |
| Days of Sales Outstanding | 94.57 | -268.35 | 115.30 | 217.20 | 141729.50 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 973.09 | -691.52 |
| Operating Cycle | 94.57 | -268.35 | 115.30 | 217.20 | 141729.50 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.70 | -0.41 | -0.34 | -1.09 | -0.89 |
| Free Cash Flow Per Share | -0.72 | -0.43 | -0.35 | -1.09 | -0.90 |
| Dividend Paid and CapEx Coverage Ratio | -61.21 | -23.11 | -38.04 | -408.81 | -133.06 |
| Capital Expenditure Coverage Ratio | -61.21 | -23.11 | -38.04 | -408.81 | -133.06 |
| Operating Cash Flow Coverage Ratio | -0.35 | -0.38 | -0.25 | -0.72 | -0.67 |
| Operating Cash Flow to Sales Ratio | -1.13 | 1.68 | -0.42 | -7.96 | -3100.40 |
| Free Cash Flow Yield | -3.67% | -14.29% | -5.25% | -30.21% | -12.30% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -38.24 | -2.10 | -6.15 | -2.21 | -5.40 |
| Price-to-Sales (P/S) Ratio | 31.19 | -12.30 | 8.12 | 26.42 | 25390.13 |
| Price-to-Book (P/B) Ratio | -10.94 | -2.17 | -132.44 | -4.66 | 9.51 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -27.22 | -7.00 | -19.05 | -3.31 | -8.13 |
| Price-to-Operating Cash Flow Ratio | -27.67 | -7.30 | -19.56 | -3.32 | -8.19 |
| Price-to-Earnings Growth (PEG) Ratio | 0.59 | -0.06 | 0.18 | -0.10 | 2.48 |
| Enterprise Value Multiple | -80.15 | -2.34 | -7.29 | -2.62 | -4.74 |
| Enterprise Value | 967.22M | 143.91M | 219.36M | 140.76M | 216.00M |
| EV to EBITDA | -80.15 | -2.34 | -7.29 | -2.62 | -4.74 |
| EV to Sales | 32.63 | -12.40 | 7.30 | 29.47 | 21600.03 |
| EV to Free Cash Flow | -28.47 | -7.05 | -17.12 | -3.69 | -6.91 |
| EV to Operating Cash Flow | -28.94 | -7.36 | -17.58 | -3.70 | -6.97 |
| Tangible Book Value Per Share | -1.78 | -1.39 | -0.05 | -0.78 | 0.77 |
| Shareholders’ Equity Per Share | -1.78 | -1.39 | -0.05 | -0.78 | 0.77 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.00 | 0.07 | 0.05 |
| Revenue Per Share | 0.63 | -0.25 | 0.82 | 0.14 | 0.00 |
| Net Income Per Share | -0.51 | -1.44 | -1.08 | -1.64 | -1.35 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 0.93 | 0.95 |
| Interest Burden | 1.77 | 1.08 | 1.25 | 1.11 | 1.05 |
| Research & Development to Revenue | 0.78 | -3.49 | 1.28 | 6.59 | 2923.40 |
| SG&A to Revenue | 0.68 | -1.73 | 0.72 | 0.00 | 1901.70 |
| Stock-Based Compensation to Revenue | 0.12 | -0.37 | 0.11 | 0.66 | 320.10 |
| Income Quality | 1.39 | 0.29 | 0.31 | 0.67 | 0.66 |
Currency in EUR

